Bristol-Myers Squibb vs Tesla: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Tesla was founded in 2003 by Martin Eberhard, Marc Tarpenning, Elon Musk and is led by Elon Musk.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Tesla
- Founded
- 2003
- Headquarters
- Austin, Texas, United States
- Current CEO
- Elon Musk
- Employees
- 134,785
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Tesla
Martin Eberhard
Martin Eberhard is an American electrical engineer who co-founded Tesla Motors and was its first CEO. He had earlier co-founded NuvoMedia, the company that made the Rocket eBook.
Marc Tarpenning
Marc Tarpenning co-founded Tesla Motors in 2003 and served in early finance, engineering and operating roles, including CFO and vice president of engineering.
Elon Musk
Elon Musk's role in Tesla's founding story is best understood as financier, chairman, product force and later crisis CEO.
JB Straubel
JB Straubel became Tesla's founding CTO and one of the most important technical architects in the company's history.
Ian Wright
Ian Wright is listed among Tesla's early founding figures because he contributed to the company's initial vehicle thinking and engineering direction.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Tesla
- Martin Eberhard2003–2007
Chief Executive Officer
Served as founding CEO from 2003 to August 2007, establishing the core technical thesis of high-performance electric vehicles and directing early engineering on the EP1 and EP2 Roadster prototypes before development delays and cost overruns prompted a board re…
Source - Ze'ev Drori2007–2008
Chief Executive Officer
Served as CEO from November 2007 to October 2008 during Tesla's initial manufacturing transition, bringing the Roadster from troubled prototypes into customer deliveries and establishing production discipline before handing leadership to Elon Musk.
Source - Elon Reeve Musk2008–present
CEO
Led Tesla's transformation from a niche electric roadster project into the world's leading EV manufacturer, scaling global Gigafactories, Supercharger infrastructure, and autonomous driving architectures.
Source
Timeline: Bristol-Myers Squibb and Tesla side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
2003Tesla
Tesla Motors Founded
Tesla Motors was founded in 2003 by Martin Eberhard and Marc Tarpenning to prove that lithium-ion batteries could power a desirable electric car.
2004Tesla
Elon Musk Leads Series A
Elon Musk led Tesla's Series A financing in 2004 and became chairman. The investment gave Tesla enough capital and public credibility to continue Roadster development.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2008Tesla
Roadster Launch
The Roadster launched in 2008 as a highway-capable electric sports car with more than 200 miles of range. It mattered because it proved an EV could be fast, premium and emotionally desirable.
2008Tesla
Elon Musk Becomes CEO
Musk became CEO in 2008 during a severe financing and production crisis. He restructured operations, secured emergency funding and pushed the company toward a clearer product sequence.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2010Tesla
Tesla IPO
Tesla went public in 2010, raising capital while still far from stable profitability. The IPO mattered because it gave Tesla access to public-market funding for product development and manufacturing.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2012Tesla
Model S Launch
The Model S launched in 2012 and moved Tesla beyond the Roadster niche. It mattered because it combined range, software, performance and premium design in a vehicle Tesla controlled more fully.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2014Tesla
Gigafactory Strategy Announced
Tesla announced the Gigafactory strategy in 2014 with Panasonic as a key partner. The move mattered because batteries were the limiting input for EV scale, cost and range.
2016Tesla
SolarCity Acquired
Tesla's 2016 SolarCity acquisition is company-specific because it changed the portfolio rather than simply adding scale. The reported value was $2.6B.
2017Tesla
Model 3 Production Crisis
The Model 3 ramp in 2017 exposed severe bottlenecks caused partly by excessive automation. The crisis mattered because Tesla's mass-market strategy depended on producing a lower-priced vehicle at high volume.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2020Tesla
S&P 500 Inclusion
Tesla joined the S&P 500 in 2020 after proving sustained profitability. The milestone mattered because it brought index-fund ownership, wider institutional attention and validation that Tesla was no longer a speculative startup.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2023Tesla
Global Price Cuts
Tesla cut prices across major markets in 2023 to defend demand and pressure competitors. The move mattered because it showed Tesla could use its direct-sales model to adjust faster than dealer-based rivals.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Tesla
$94.8B Revenue and Delivery Decline
In FY2025, Tesla reported $94.8B in revenue and delivered 1,636,129 vehicles. The milestone mattered because revenue and deliveries both showed the company had entered a more mature, contested phase.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Tesla
- Maxwell Technologies2019$218M
- DeepScale2019Undisclosed
- Hibar Systems2019Undisclosed
- Perbix Machine Company2017$10.5M
- SolarCity2016$2.6B
- Grohmann Engineering2016$135M
Questions about Bristol-Myers Squibb vs Tesla
Who is the CEO of Bristol-Myers Squibb Company and Tesla, Inc.?
Bristol-Myers Squibb Company is led by Christopher Boerner and Tesla, Inc. is led by Elon Musk. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Tesla, Inc.?
Bristol-Myers Squibb Company was founded in 1887 — 116 years before Tesla, Inc., which was founded in 2003. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Tesla, Inc..
How many employees does Bristol-Myers Squibb Company have compared to Tesla, Inc.?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Tesla, Inc. employs approximately 134,785. Tesla, Inc. has the larger workforce at 134,785 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Tesla, Inc. headquartered?
Both Bristol-Myers Squibb Company and Tesla, Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Bristol-Myers Squibb Company and Tesla, Inc.?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Tesla, Inc. was founded by Martin Eberhard, Marc Tarpenning, Elon Musk, JB Straubel, Ian Wright.
Which company has a longer operating history — Bristol-Myers Squibb Company or Tesla, Inc.?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Tesla, Inc. has been in operation for around 23 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Tesla overview